A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis
A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(3)
1 other identifier
interventional
20
1 country
1
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 25, 2012
CompletedFirst Posted
Study publicly available on registry
June 27, 2012
CompletedMay 30, 2014
May 1, 2014
June 25, 2012
May 29, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The severity score of the pelvic pain
8 weeks
Study Arms (2)
Drug:KLH-2109 lower dose
EXPERIMENTALDrug:KLH-2109 higher dose
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Female patients with endometriosis
You may not qualify if:
- Patients with clinically significant hepatic, renal, or cardiovascular dysfunction
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Japan
Tokyo and Other Japanese City, Japan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 25, 2012
First Posted
June 27, 2012
Last Updated
May 30, 2014
Record last verified: 2014-05